Plus Therapeutics, Inc. (PSTV)

1,8000 -0,0400 (-2,17%) Alla chiusura: 04:00PM EDT

Plus Therapeutics, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
737 255 7194
https://plustherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 20

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Marc H. Hedrick M.B.A., M.D.	President, CEO & Director	945,34k	N/D	1963
Mr. Andrew J. Sims CPA	VP of Finance & CFO	498,51k	N/D	1973
Dr. Norman D. LaFrance FACNP, FACP, M.D.	Chief Medical Officer & Senior VP	646,02k	N/D	1948
Ms. Desiree Smith	Corporate Controller, Principal Financial & Accounting Officer	N/D	N/D	1964
Dr. John K. Fraser	Chief Scientist	N/D	N/D	1961

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Governance aziendale

L'ISS Governance QualityScore di Plus Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.